Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Core Insights - Alector, Inc. announced results from the INVOKE-2 Phase 2 clinical trial for AL002, which did not meet its primary endpoint of slowing Alzheimer's disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB) [1] - The company is halting the long-term extension study based on these results and plans to further explore TREM2 biology [2] - Alector is committed to advancing its pipeline of drug candidates for neurodegenerative diseases, including ongoing trials for latozinemab and AL101/GSK4527226 [3] Clinical Trial Results - The INVOKE-2 trial was a randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer's disease, with no significant effects on clinical and functional endpoints or Alzheimer's fluid biomarkers [1][7] - MRI changes resembling amyloid-related imaging abnormalities (ARIA) were observed, primarily in participants treated with AL002 [1] Pipeline and Future Plans - Alector is advancing its drug candidates, with topline data from the INFRONT-3 Phase 3 trial of latozinemab expected in late 2025 or early 2026 [3] - The PROGRESS-AD Phase 2 trial for AL101/GSK4527226 has reached over one-third of its target enrollment of 282 participants [3] Technology Development - The company is developing its proprietary blood-brain barrier technology platform, Alector Brain Carrier (ABC), aimed at enhancing therapeutic delivery and improving patient outcomes [4][9] Workforce and Financials - Alector is reducing its workforce by approximately 17% to align resources with strategic priorities [5] - As of September 30, 2024, Alector has $457.2 million in cash and equivalents, expected to provide runway through 2026 [6]